AEG35156-204: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas.
Phase of Trial: Phase I/II
Latest Information Update: 12 Jul 2011
At a glance
- Drugs AEG 35156 (Primary)
- Indications B cell lymphoma; Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Aegera Therapeutics
- 12 Jul 2011 Planned End Date changed from 1 Dec 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 12 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Mar 2010 Planned end date changed from 1 Sep 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.